64
countries are deployment ready
~$35B
of combined forecast for peak annual sales for drugs and IVD assets on our platform
80%+
disease states covered
CSL Behring leveraged the BrightInsight Platform® to launch a mobile app for adult patients with rare diseases who are taking Hizentra.
Read Now
Contact us today to start a conversation about how we can help turn your greatest revenue leak into your most powerful growth lever.
Contact us